Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.

New Prostate Cancer Test Better Than PSA Test

By Labmedica International staff writers
Posted on 30 May 2011
A new test for prostate cancer that measures levels of prostate specific antigen (PSA) as well as six specific antibodies found in the blood of men with the disease is more sensitive and more specific than the conventional PSA test used today, according to a new study.

Researchers at the University of California Los Angeles (UCLA; USA) developed the new test, called the A+PSA assay, which checks simultaneously for PSA and antibodies to six prostate-cancer associated antigens in a single reaction test done in a laboratory. The six specific prostate-cancer associated antigens include NY-ESO-1, SSX-2,4, XAGE-lb, AMACR, p90 and LEDGF, which are found predominantly in patients with prostate cancer and not in benign prostate conditions. The new test takes about two hours, similar to the PSA test.

The test results in an index used to diagnose prostate cancer, with a score of 0-0.5 indicating a benign result and 0.5-1 indicating the presence of cancer. In the new test, sensitivity--the percentage of men with prostate cancer who were correctly identified as having a malignancy--was 79%, compared to the 52% found in PSA testing. Specificity--the percentage of healthy men who were correctly identified as not having prostate cancer--was 84%, compared to the 79% found when testing for PSA alone. Additionally, while the rate of false-positives using conventional PSA testing is 21%, the new A+PSA assay delivers a false-positive rate of 16%. The study was published in the May 2011 issue of Translational Medicine.

"Science has improved so much since the PSA test was developed and I think it's time for a more specific and sensitive test to be developed," said senior author Gang Zeng, MD, PhD, an associate professor of urology. "I think we have a test that has great potential to improve the diagnosis of prostate cancer. I knew it would be better than the classic PSA test, but I was amazed at how much better it really was in this study."

"While measuring PSA is useful in identifying men with prostate cancer, some men with prostate cancer have a normal PSA level and small elevations in PSA above normal may be produced both by prostate cancer as well as an enlarged but benign prostate," added coauthor associate professor of urology Allan Pantuck, MD, MS. "Combining PSA with a panel of tests that measure an individual man's anticancer immune response may better identify who has prostate cancer and who can be spared an unnecessary invasive biopsy."

The conventional PSA test for prostate cancer has been used for nearly 30 years and is not specific enough in delineating between malignancies and nonmalignant diseases of the prostate, such as benign prostatic hyperplasia (BPH), an enlarging of the prostate common in aging men that increases PSA levels.

Related Links:

University of California Los Angeles




DIASYS DIAGNOSTIC SYSTEMS
77 ELEKTRONIKA
KARL HECHT GMBH & CO KG

Channels

Genetic Tests

view channel
Image: Globoid cell leukodystrophy: Mulinucleated macrophages (\"globoid cells\") and loss of myelinated fibers in a case of Krabbe\'s leukodystrophy (Photo courtesy of Wikimedia Commons).

Advanced Next-Generation Sequencing Assay Kit Now Available for the Diagnosis of Leukodystrophy

An advanced next-generation sequencing (NGS) assay kit is now available to augment the use of MRI scans to diagnose the class of brain disorders known as leukodystrophies. Leukodystrophies are genetic... Read more

Hematology

view channel
Image: The ADVIA 2120 Hematology System (Photo courtesy of Siemens).

Preoperative Blood Cell Ratios Predict Endometrial Cancer Survival

The variations in systemic inflammatory response biomarker levels have been associated with adverse clinical outcome in various malignancies and the host response to malignant tumors is characterized by... Read more

Lab Tech.

view channel
Image: Verigene System instrumentation consists of a Verigene Reader and one or multiple Verigene Processor SPs (Photo courtesy of Nanosphere).

Directed Molecular Diagnostic Tests Highlight Recent Microbiology Conference

The performance of a series of directed molecular diagnostic tests was confirmed by several studies presented at a recent microbiology conference. Nanosphere (Northbrook, IL, USA) manufactures tests... Read more

Industry News

view channel

Cancer Genetics Expands Access to Proprietary Diagnostics Through Agreement with Harvard Pilgrim

Under the terms of a new agreement between Cancer Genetics, Inc. (CGI; Morrisville, NC, USA) and Harvard Pilgrim Healthcare (Hartford, CT; USA), a health care network covering over one million people throughout Massachusetts, Connecticut, and Maine, CGI will offer its cancer diagnostic services to individuals covered under... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.